Demographic information on HIV-1–infected patients, healthy uninfected controls, and HIV-1–uninfected patients with ACS and stable CAD
| . | HIV-1–uninfected controls (n = 23) . | HIV-1–infected patients with VL < 400 copies/mL (n = 39) . | HIV-1–infected patients with VL > 400 copies/mL (n = 18) . | CAD controls (n = 16) . | ACS patients (n = 10) . |
|---|---|---|---|---|---|
| Median age, y, (range) | 40 (24-65) | 46 (25-73) | 43 (23-55) | 62 (37-73) | 67 (37-84) |
| Sex, % female | 61% | 15% | 39% | 38% | 70% |
| Race, % nonwhite | 30% | 57% | 78% | 0% | 71% |
| Median CD4+ T-cell count, cells/μL, (range) | NR | 578 (201-1463) | 398 (88-713) | NA | NA |
| Median plasma HIV-1 RNA, copies/mL, (range) | NA | 48 (48-264) | 8446 (771-340 192) | NA | NA |
| Hepatitis C infection | NR | 16% | 22% | 0% | 0% |
| On HAART | NA | 100% | 44% | NA | NA |
| Diabetes | NR | 18% | 0% | 6% | 43% |
| Diagnosed hypertension | N.R | 45% | 33% | 25% | 70% |
| Current smoker | 18% | 59% | 61% | 6% | 40% |
| Family history of premature CAD | NR | NR | NR | 13% | 10% |
| Aspirin use* | NR | 13% | 6% | 44% | 70% |
| Statin use* | NR | 25% | 6% | 31% | 70% |
| Median total cholesterol, mg/dL (range) | NR | NR (149-297) | NR (98-218) | 189† | 167 |
| Median low-density lipoprotein, mg/dL (range) | NR (33-249) | 103 (40-158) | 79.5 (89-196) | 113 (42-159)† | 104 |
| Median high-density lipoprotein, mg/dL (range) | NR (24-86) | 47 (25-69) | 38 (33-65) | 44 (22-61)† | 39 |
| Median triglycerides, mg/dL (range) | NR (47-1290) | 117 (53-312) | 144.5 (50-325) | 140 (59-193)† | 141 |
| Framingham Risk Score, median/mean (range) | NR | 7.0/9.0 (1-27) | 7.0/8.4 (1-22) | 7.5/10.7 (1-31)† | 9.0/10.5 (2-20) |
| . | HIV-1–uninfected controls (n = 23) . | HIV-1–infected patients with VL < 400 copies/mL (n = 39) . | HIV-1–infected patients with VL > 400 copies/mL (n = 18) . | CAD controls (n = 16) . | ACS patients (n = 10) . |
|---|---|---|---|---|---|
| Median age, y, (range) | 40 (24-65) | 46 (25-73) | 43 (23-55) | 62 (37-73) | 67 (37-84) |
| Sex, % female | 61% | 15% | 39% | 38% | 70% |
| Race, % nonwhite | 30% | 57% | 78% | 0% | 71% |
| Median CD4+ T-cell count, cells/μL, (range) | NR | 578 (201-1463) | 398 (88-713) | NA | NA |
| Median plasma HIV-1 RNA, copies/mL, (range) | NA | 48 (48-264) | 8446 (771-340 192) | NA | NA |
| Hepatitis C infection | NR | 16% | 22% | 0% | 0% |
| On HAART | NA | 100% | 44% | NA | NA |
| Diabetes | NR | 18% | 0% | 6% | 43% |
| Diagnosed hypertension | N.R | 45% | 33% | 25% | 70% |
| Current smoker | 18% | 59% | 61% | 6% | 40% |
| Family history of premature CAD | NR | NR | NR | 13% | 10% |
| Aspirin use* | NR | 13% | 6% | 44% | 70% |
| Statin use* | NR | 25% | 6% | 31% | 70% |
| Median total cholesterol, mg/dL (range) | NR | NR (149-297) | NR (98-218) | 189† | 167 |
| Median low-density lipoprotein, mg/dL (range) | NR (33-249) | 103 (40-158) | 79.5 (89-196) | 113 (42-159)† | 104 |
| Median high-density lipoprotein, mg/dL (range) | NR (24-86) | 47 (25-69) | 38 (33-65) | 44 (22-61)† | 39 |
| Median triglycerides, mg/dL (range) | NR (47-1290) | 117 (53-312) | 144.5 (50-325) | 140 (59-193)† | 141 |
| Framingham Risk Score, median/mean (range) | NR | 7.0/9.0 (1-27) | 7.0/8.4 (1-22) | 7.5/10.7 (1-31)† | 9.0/10.5 (2-20) |